Biopharmaceutical contract manufacturing organizations (CMOs) and contract research organizations (CROs) play a key role in drug development by providing development and manufacturing services to pharmaceutical and biotechnology companies. These organizations assist drug developers in conducting clinical trials, manufacturing drugs, and other related services. The biopharmaceutical industry has seen significant growth in the development of complex biologics such as monoclonal antibodies, recombinant proteins, and gene and cell therapies in recent years. Developing such advanced therapies poses several technical challenges related to manufacturing and testing. This has increased the demand for specialized contract services from CMOs and CROs with expertise in biologics development.

The global Biopharmaceutical CMO and CRO Market is estimated to be valued at US$ 36.2 Bn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One of the key trends driving the growth of the biopharmaceutical CMO and CRO market is the increasing outsourcing of drug development activities by pharmaceutical and biotech companies. Developing advanced biologic drugs requires significant capital investment and a wide range of specialized expertise that is not available in-house with many smaller drug developers. This has prompted increased outsourcing of functions like clinical trials, preclinical testing and manufacturing to well-established contract service providers. CMOs and CROs with advanced capabilities for biologics are benefitting from this trend as outsourcing is expected to continue rising to efficiently develop new drugs with constrained resources.

Segment Analysis

The global biopharmaceutical CMO and CRO market is dominated by the CMO sub-segment. The CMOs provide efficient contract development and manufacturing services to biopharmaceutical companies of all sizes with technologies required to manufacture complex biologics. They have expertise in cell line and process development coupled with scale-up of biomanufacturing processes. With increasing demand for biologics, biopharmaceutical companies are outsourcing the manufacturing process to expert CMOs to focus on core competencies of research and development. This has boosted the growth of the CMO sub-segment over the forecast period.

Key Takeaways

The Global Biopharmaceutical CMO and CRO market size is expected to witness high growth. Regional analysis shows that North America currently dominates the market owing to presence of large number of biopharmaceutical companies and research organizations in the region and growing number of clinical trials. However, Asia Pacific region is expected to grow at the fastest pace over the forecast period due to availability of low-cost yet skilled labor and ease of conducting clinical trials.

Key players operating in the biopharmaceutical CMO and CRO market are Allphase Clinical Research, AlcheraBio, Alcami, Akos Urgent Care, Agilent, AGC Biologics, Affinity Life Sciences, Inc., Actimus Bio, ACI Clinical, Accumedix, Inc., Absorption Systems, A10 Clinical Solutions, Albuquerque Clinical Trials (ACT), Ajinomoto Bio-Pharma Services, Advanced Clinical Services LLC, ACM Global Laboratories, Accelerated Enrollment Solutions, AbbVie Contract Manufacturing, Advanced BioScience Laboratories, Advanced Clinical Research Institute, and Alliance for Clinical Trials in Oncology, among others.

The global biopharmaceutical CMO and CRO market is expected to witness high growth. Regional analysis shows that Europe is also an important market. The key factors contributing to the growth in Europe include presence of large pharmaceutical companies and growing focus on outsourcing production services by these players.

Key players operating in the biopharmaceutical CMO and CRO market are expanding their presence globally through partnerships and acquisitions to strengthen service capabilities and gain access to newer geographies. They are also investing in advanced technologies and capabilities to cater to the complex requirements of biopharmaceutical manufacturing and clinical trials. This is helping them gain better footing in the highly competitive market.

Get More Insights Here

https://healthcarelatesteditionnews.blogspot.com/2023/12/growing-needs-for-complex-drug.html